Establishment Labs Holdings Inc.

NASDAQ:ESTA

Medical - Devices

Healthcare
$70.80 +3.21%

+$2.65 today

Market cap
$2.11B
Beta
1.11
P/E (TTM)
-57.6
EPS (TTM)
-$1.48
52W Low $33.35High $86.00

Volume 0.38M

Average 0.50M

ESTA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Establishment Labs Holdings Inc.NASDAQ: ESTA

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development dips below year-ago levels

Q3 FY2026 research & development of $4.31M fell 5.3% year over year, behind the +0.6% change in trailing-twelve-month research & development. Sequentially, it fell 15.4% from the prior quarter. Over 3 fiscal years it compounded at -0.0% a year.

Context

  • Research & development amounted to 9.6% of revenue in FY2025, down 2.3 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -5.3% toward the trailing-twelve-month pace of +0.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$4.31M-15.4% QoQ
Last fiscal yearDec 2025
$20.25M+2.7% YoY
LTMSep 2026
$20.08M+0.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.3%——
1 year+2.7%——
3-year CAGR-0.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
20.25M USD
Year-over-year change
+2.7%
4-year CAGR
+2.5%

Research & Development vs competitors

How ESTA compares with its peers on the latest reported figures

  • ESTA's LTM Sep 2026 research & development of $20.08M is the 2nd highest of the 4 companies compared; the peer median is $13.97M.
  • Its year-over-year change of +0.6% is the 3rd highest of 4, against a peer median of +8.0%.
  • Research & development amounts to 7.6% of revenue for ESTA, versus a peer median of 5.9%.
ESTA Competitors Peer median
Research & Development for ESTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$97.75M -13.6%-0.7%5.9%
ESTAEstablishment Labs Holdings Inc.LTM Sep 2026$20.08M +0.6%-0.0%7.6%
INMDInMode Ltd.LTM Mar 2026$13.97M +11.6%+2.3%3.7%
TELATELA Bio, Inc.LTM Jun 2026$9.54M +8.0%+1.0%11.9%
Peer median (excluding ESTA) $13.97M+8.0%+1.0%5.9%

Competitors are the stored peer set for ESTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue126.68M161.7M165.15M166.03M211.08M
Cost of Revenue41.28M55.11M58.17M56.5M64.77M
Gross Profit85.4M106.6M106.98M109.53M146.31M
Gross Margin67.4%65.9%64.8%66.0%69.3%
Research & Development18.32M20.27M26.43M19.71M20.25M
Selling, General & Admin92.23M125.98M145.58M139.81M165.07M
Operating Expenses110.54M146.25M172M159.51M185.32M
Depreciation & Amortization4.12M4.34M4.88M7.58M10.47M
EBITDA(26.53M)(56.73M)(58.31M)(56.22M)(22.29M)
EBITDA Margin-20.9%-35.1%-35.3%-33.9%-10.6%
Operating Income(25.14M)(39.66M)(65.03M)(49.99M)(39.01M)
Operating Margin-19.8%-24.5%-39.4%-30.1%-18.5%
Interest Income23K87K1.02M1.48M423K
Interest Expense9.06M11.76M15.39M20.83M25.26M
Other Income / Expenses(14.57M)(33.17M)(13.56M)(34.64M)(19.01M)
Income Before Tax(39.71M)(72.82M)(78.58M)(84.63M)(58.02M)
Pre-Tax Margin-31.3%-45.0%-47.6%-51.0%-27.5%
Income Tax Expense1.43M2.39M(81K)(32K)(6.96M)
Net Income(41.14M)(75.21M)(78.5M)(84.6M)(51.06M)
Net Margin-32.5%-46.5%-47.5%-51.0%-24.2%
EPS (Basic)(1.72)(3.08)(3.07)(3.00)(1.72)
EPS (Diluted)(1.72)(3.08)(3.07)(3.00)(1.72)
Weighted Avg Shares23.97M24.46M25.6M28.16M29.62M
Weighted Avg Shares (Diluted)23.97M24.46M25.6M28.16M29.62M

Establishment Labs Holdings Inc.

NASDAQ:ESTA

Intrinsic Alpha fair value

Locked

Current Price

$70.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.